vTv Therapeutics (VTVT) EBITDA (2014 - 2026)
vTv Therapeutics (VTVT) posted EBITDA of $23.3 million for Q1 2026, up 395.03% sequentially from -$7.9 million in Q4 2025, and up 457.73% YoY from $4.2 million in Q1 2025.
vTv Therapeutics (VTVT) EBITDA (2014 - 2026) Analysis & Trends
vTv Therapeutics has reported EBITDA for 13 years, with the latest figure at $23.3 million in Q1 2026.
- Quarterly EBITDA rose 457.73% year-over-year to $23.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.0 million (up 87.86% YoY) and the FY2025 annual result came in at -$32.8 million, down 35.68% from the prior year.
- EBITDA grew to $23.3 million in Q1 2026 per VTVT's latest filing, from -$7.9 million in the prior quarter.
- Over five years, EBITDA peaked at $23.3 million in Q1 2026 and troughed at -$10.7 million in Q3 2025.
- A 5-year average of -$4.8 million and a median of -$6.5 million in 2022 frame the typical range for EBITDA.
- The sharpest annual moves came in 2022 and 2026: EBITDA plunged 254.9% in 2022, then jumped 457.73% in 2026.
- Over 5 years, EBITDA stood at -$6.3 million in 2022, then climbed by 25.79% to -$4.7 million in 2023, then fell by 3.93% to -$4.9 million in 2024, then slumped by 61.18% to -$7.9 million in 2025, then soared by 395.03% to $23.3 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered $23.3 million, -$7.9 million, and -$10.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | vTv Therapeutics | 373.77 Mn | 373.77 Mn | - | -13.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -13.93 Mn |
| Mar 31, 2026 | 23.26 Mn |
| Dec 31, 2025 | -7.89 Mn |
| Sep 30, 2025 | -10.70 Mn |
| Jun 30, 2025 | -7.72 Mn |
| Mar 31, 2025 | -6.50 Mn |
| Dec 31, 2024 | -4.89 Mn |
| Sep 30, 2024 | -6.51 Mn |
| Jun 30, 2024 | -7.16 Mn |
| Mar 31, 2024 | -5.63 Mn |
| Dec 31, 2023 | -4.71 Mn |
| Sep 30, 2023 | -5.37 Mn |
| Jun 30, 2023 | -8.00 Mn |
| Mar 31, 2023 | -7.43 Mn |
| Dec 31, 2022 | -6.34 Mn |
| Sep 30, 2022 | -5.69 Mn |
| Jun 30, 2022 | -4.03 Mn |
| Mar 31, 2022 | -6.48 Mn |
| Dec 31, 2021 | -11.11 Mn |
| Sep 30, 2021 | -1.60 Mn |